Questions

1. Clinical Diagnosis:
   • Acute Hemorrhagic Conjunctivitis (AHC) / Epidemic Hemorrhagic Conjunctivitis.
2. Etiologic Agents:
   • Primary causative enteroviruses:
     • Enterovirus 70 (EV-70; genus Enterovirus, family Picornaviridae)
     • Coxsackievirus A24 variant (CA24v)
   • Other viral causes:
     • Adenovirus species (notably Human Mastadenovirus D serotypes 8, 19, 37, and serotype 11)
3. Comparison with Epidemic Keratoconjunctivitis (EKC):
   • Incubation Period: AHC has an ultra-short incubation period of 12 to 48 hours, whereas EKC (Adenovirus) exhibits a longer incubation period of 7 to 14 days.
   • Corneal Involvement: In AHC, corneal involvement is uncommon, mild, and transient (fine punctate epithelial keratitis that resolves rapidly). In EKC, subepithelial corneal infiltrates (nummular keratitis) are hallmark features that develop 1–2 weeks post-infection and can persist for months to years, impairing visual acuity.
   • Systemic / Neurological Sequelae: EV-70 infection can rarely lead to severe acute neurological manifestations, specifically a polio-like lower motor neuron acute flaccid paralysis (radiculomyelitis) appearing 1 to 8 weeks after conjunctivitis.
4. Management and Infection Control Protocol:
   • Supportive Medical Therapy:
     • Cold compresses applied to closed eyelids for symptomatic relief.
     • Preservative-free artificial tear lubricants (e.g., Carboxymethylcellulose 0.5% drops 4 to 6 times daily).
     • Oral analgesics: Paracetamol (15 mg/kg/dose every 6 hours PRN) or Ibuprofen (10 mg/kg/dose every 8 hours PRN).
     • Avoid topical corticosteroids (contraindicated; prolongs viral replication and increases risk of secondary bacterial/fungal keratitis).
     • Topical broad-spectrum prophylactic antibiotic drops (e.g., Moxifloxacin 0.5% or Tobramycin 0.3% TID) only if secondary bacterial superinfection is suspected.
   • Institutional Outbreak Containment:
     • Strict cohorting and school exclusion of symptomatic children for at least 7 to 10 days from symptom onset or until complete resolution of discharge.
     • Hand hygiene: Frequent washing with soap and water (alcohol-based hand rubs are less effective against non-enveloped enteroviruses).
     • Contact precautions: Disinfection of communal surfaces, doorknobs, and bedding using 0.5% sodium hypochlorite (bleach) solution. Avoid sharing towels, pillows, or optical devices.

1. Funduscopic Findings and Primary Diagnosis:
   • Fundus Findings: Hyperemic, elevated optic disc with blurring and obliteration of the disc margins, radial capillary dilatation (telangiectatic vessels) over the disc surface, engorged peripapillary retinal veins, and surrounding flame-shaped splinter hemorrhages (Papillitis / anterior optic disc edema).
   • Primary Diagnosis: Acute Optic Neuritis (Anterior Optic Neuritis / Papillitis).
2. Pathognomonic Psychophysical and Pupillary Signs:
   • Relative Afferent Pupillary Defect (RAPD / Marcus Gunn pupil): Paradoxical dilatation of the affected pupil when the light source is swung from the normal to the affected eye during the swinging-flashlight test.
   • Dyschromatopsia: Profound impairment of color perception disproportionate to visual acuity loss, particularly red-green desaturation (tested via Ishihara plates or red desaturation test).
   • Visual Field Defect: Predominantly a central or cecocentral scotoma, though nerve fiber bundle defects (arcuate, altitudinal) can occur.
   • Pulfrich Phenomenon: Altered stereoscopic depth perception of moving objects.
   • Uhthoff Phenomenon: Transient worsening of vision induced by an increase in core body temperature (exercise, hot shower).
3. Etiologic Categorization:
   • Demyelinating / Autoimmune Spectrum:
     • Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) — most common in pediatric optic neuritis, frequently bilateral.
     • Neuromyelitis Optica Spectrum Disorder (NMOSD; anti-AQP4 positive).
     • Multiple Sclerosis (MS; clinically isolated syndrome).
     • Acute Disseminated Encephalomyelitis (ADEM).
   • Infectious / Post-infectious:
     • Post-viral demyelination (following EBV, Varicella-Zoster, Influenza, Measles, Mumps).
     • Bartonella henselae (Cat scratch disease / neuroretinitis with macular star).
     • Lyme disease (Borrelia burgdorferi), Syphilis, Tuberculosis.
   • Toxic / Metabolic / Genetic:
     • Leber Hereditary Optic Neuropathy (LHON; mitochondrial DNA point mutations: m.11778G>A).
     • Toxic amblyopia (Methanol poisoning, Ethambutol, Linezolid toxicity).
     • Vitamin B12 / Folate deficiency.
4. Diagnostic Workup and Treatment Protocol:
   • Diagnostic Workup:
     • MRI of Brain and Orbits with IV Gadolinium: T1 post-contrast fat-suppressed sequences (shows optic nerve hyperintensity and thickening); T2/FLAIR brain imaging to evaluate for white matter demyelinating plaques.
     • Serological Autoantibody Testing: Serum cell-based assay for MOG-IgG and Aquaporin-4 (AQP4-IgG) antibodies.
     • Lumbar Puncture: CSF cell count, protein, oligoclonal bands (OCBs), and IgG index.
   • First-Line Pulse Corticosteroid Therapy:
     • IV Methylprednisolone:
       $$ > \text{Dose} = 30\text{ mg/kg/day IV (Maximum: } 1000\text{ mg/day)} \text{ administered once daily over 1–2 hours for } 3 \text{ to } 5 \text{ consecutive days}. > $$
     • Followed by Oral Prednisolone Taper:
       $$ > \text{Dose} = 1\text{ to } 2\text{ mg/kg/day PO}, \text{ gradually tapered over } 2 \text{ to } 4 \text{ weeks} > $$
       (Note: In MOGAD-associated optic neuritis, slow oral steroid taper over 1–3 months is mandatory to prevent early rebound relapse).

1. Clinical Diagnosis:
   • Acute Otitis Externa (AOE) / Diffuse Otitis Externa ("Swimmer's ear").
2. Microbiological Etiology:
   • Primary Bacterial Pathogens:
     • Pseudomonas aeruginosa (~50% to 65% of cases)
     • Staphylococcus aureus (~15% to 30% of cases)
   • Primary Fungal Pathogens (Otomycosis):
     • Aspergillus niger (black particulate debris)
     • Candida albicans / other Candida species
3. Differentiation: Acute Otitis Externa (AOE) vs. Acute Otitis Media with Perforation (AOM):
   • Tragal / Pinna Manipulation: Severe pain elicited by tragal pressure or pinna movement in AOE; absent or minimal in uncomplicated AOM.
   • Canal Pathology: Diffuse circumferential edema, erythema, and lumen obliteration of the external auditory canal in AOE; in AOM, the canal skin is typically normal (except for secondary drainage irritation) and the infection originates in the middle ear cleft.
   • Tympanic Membrane & Pneumatic Otoscopy: In AOE, the tympanic membrane is structurally intact (though often obscured); in perforated AOM, a discrete perforation with middle ear mucosal edema or pulsatile discharge through the defect is observed.
4. Management Plan:
   • Step 1: Aural Toilet:
     • Gentle mechanical debridement under direct visualization via suctioning or dry swabbing to clear macerated skin, cerumen, and purulent exudate, allowing topical medications to contact canal epithelium. (Avoid syringing/irrigation if TM status is unconfirmed).
   • Step 2: Ear Wick Placement:
     • Indicated because the ear canal is occluded by severe edema (>50% luminal closure). A compressed expandable polyvinyl alcohol wick (Pope wick) or ribbon gauze is inserted to act as a stent and vehicle for drug delivery into the medial canal. The wick is left in place for 48 to 72 hours until swelling subsides.
   • Step 3: Topical Pharmacotherapy:
     • Topical Fluoroquinolone + Corticosteroid combination (safe for suspected or unvisualized tympanic membrane perforations):
       • Ciprofloxacin 0.3% + Dexamethasone 0.1% otic suspension: Instill 4 drops into the affected ear twice daily for 7 days.
       • Alternative: Ofloxacin 0.3% otic drops: 5 drops twice daily for 7 to 10 days.
       • (Aminoglycoside-containing drops like Neomycin/Polymyxin B should be strictly avoided when TM cannot be visualized due to ototoxicity risk).
   • Step 4: Systemic Analgesia:
     • Ibuprofen:
       $$ > \text{Dose} = 10\text{ mg/kg/dose orally every } 6\text{ to } 8\text{ hours as needed (Maximum: } 40\text{ mg/kg/day or } 2400\text{ mg/day)}. > $$
     • Paracetamol (Acetaminophen):
       $$ > \text{Dose} = 15\text{ mg/kg/dose orally every } 4\text{ to } 6\text{ hours as needed (Maximum: } 75\text{ mg/kg/day or } 4000\text{ mg/day)}. > $$

1. Congenital Ocular Malformation:
   • Congenital Aniridia (near-total or subtotal hypoplasia/absence of the iris).
2. Genetic Basis:
   • Causative Gene: PAX6 gene (Paired Box 6 — master control transcription factor for oculogenesis).
   • Chromosomal Locus: Chromosome 11p13.
   • Inheritance Pattern:
     • Familial Aniridia (~two-thirds of cases): Autosomal dominant with high penetrance and variable expressivity (caused by intragenic mutations or deletions of PAX6).
     • Sporadic Aniridia (~one-third of cases): De novo mutations or contiguous microdeletions of chromosome 11p13.
3. Associated Progressive Ocular Complications:
   • Foveal / Macular Hypoplasia: Leading to profound sensory congenital nystagmus and permanently diminished visual acuity (typically 20/100 to 20/400).
   • Aniridia-Associated Keratopathy (AAK): Secondary to limbal stem cell deficiency, resulting in peripheral corneal pannus, recurrent epithelial breakdowns, corneal scarring, and vascularization.
   • Secondary Glaucoma: Develops in 50% to 75% of patients (typically during late childhood or adolescence) due to progressive developmental occlusion of the trabecular meshwork by rudimentary iris tissue.
   • Cataract / Ectopia Lentis: Early-onset anterior/posterior subcapsular cataract, cortical opacities, or lens subluxation/dislocation due to fragile, hypoplastic zonules.
   • Optic Nerve Hypoplasia: Involving underdevelopment of the optic papilla and decreased axons.
4. Syndromic Association and Surveillance Protocol:
   • Syndrome: WAGR Syndrome (contiguous gene deletion of 11p13 involving both PAX6 and WT1):
     • Wilms tumor (nephroblastoma)
     • Aniridia
     • Genitourinary anomalies (cryptorchidism, hypospadias, streak gonads)
     • Range of developmental delay / intellectual disability
   • Associated Malignancy: Wilms tumor (occurs in ~50% of children with WAGR syndrome).
   • Radiological Surveillance Protocol:
     • High-resolution Abdominal Ultrasound: Every 3 months from birth until the child reaches 8 years of age.
     • Genetic testing (Chromosomal Microarray / FISH / MLPA for WT1 deletion) must be performed immediately in all cases of sporadic aniridia to rule out WAGR syndrome.

1. Definitive Clinical Diagnosis:
   • Chalazion (Meibomian Cyst / Lipogranuloma of the eyelid).
2. Pathophysiology and Differentiation:
   • Pathophysiologic Mechanism:
     • Caused by non-infectious obstruction of the meibomian gland orifice and duct. Stagnant lipid secretions (sebaceous fluid) extravasate into the surrounding tarsal plate stroma, provoking a chronic foreign-body lipogranulomatous inflammatory response characterized by lipid-laden epithelioid macrophages, multinucleated foreign-body giant cells, lymphocytes, and plasma cells.
   • Contrast with Hordeolum Externum (Stye):
     • Anatomical Structure: Hordeolum externum arises from the superficial glands of the eyelash margin (Glands of Zeis [modified sebaceous] or Glands of Moll [modified apocrine]); Chalazion arises from the deep meibomian glands embedded within the dense fibrous tarsal plate.
     • Etiology: Hordeolum externum is an acute, painful, suppurative bacterial microabscess (predominantly Staphylococcus aureus); Chalazion is a chronic, painless, sterile lipogranulomatous inflammation.
3. Conservative Non-Surgical Management:
   • Warm Compresses: Apply warm, moist washcloths or thermal eyelid pads for 10 to 15 minutes, 3 to 4 times daily, to liquefy thickened, inspissated meibomian lipids.
   • Lid Hygiene & Massage: Gentle digital vertical expression toward the lid margin following heat application to evacuate gland contents, along with dilute baby shampoo or hypochlorous acid lid scrubs.
   • Expected Outcome: Spontaneous resolution occurs in approximately 25% to 50% of cases within 4 to 8 weeks with compliant conservative therapy.
4. Surgical Indications, Technique, and Systemic Medical Dosing:
   • Indications for Surgical Intervention:
     • Failure of resolution after 4 to 8 weeks of compliant conservative therapy.
     • Large nodule exerting mechanical pressure on the cornea causing significant corneal astigmatism, visual axis obstruction, and risk of refractive/deprivation amblyopia.
     • Significant cosmetic deformity or persistent secondary mechanical ptosis.
   • Surgical Procedure and Incision Orientation:
     • Incision and Curettage (I&C) under local (or general) anesthesia using a chalazion clamp.
     • The incision must be made vertically (perpendicular to the lid margin) on the palpebral conjunctival surface.
     • Rationale: A vertical incision parallels the long axis of the meibomian glands, avoiding transection of adjacent uninvolved meibomian gland ducts and preventing scarring/notching of the eyelid margin.
   • Systemic Therapy for Recurrent / Blepharitis-Associated Cases:
     • Indicated in chronic blepharokeratoconjunctivitis, severe ocular rosacea, or recurrent multi-focal chalazia:
       • Oral Azithromycin (preferred in children <8 years):
         $$ > \text{Dose} = 10\text{ mg/kg/day orally once daily for 3 consecutive days per week, repeated for 3 weeks}. > $$
       • Oral Doxycycline (approved strictly in children $\ge$ 8 years of age due to risk of enamel hypoplasia/teeth staining):
         $$ > \text{Dose} = 100\text{ mg orally once daily (or 1.5–2 mg/kg/dose BID) for 4 to 8 weeks} \text{ (acts primarily via anti-inflammatory and matrix metalloproteinase inhibition mechanisms)}. > $$

1. Fundoscopic Finding:
   • Cherry-red spot at the macula / fovea centralis.
2. Pathophysiological Mechanism:
   • Parafoveal Opacification: The parafoveal retina normally contains multiple layers of retinal ganglion cells. In lysosomal storage disorders, abnormal accumulation of non-metabolized substrates (e.g., GM2 gangliosides or sphingomyelin) distends these ganglion cell perikarya, making the parafoveal tissue thick, pale, cloudy, and yellowish-white.
   • Foveal Contrast: The fovea centralis lacks ganglion cells and consists almost entirely of tightly packed cone photoreceptors and their inner segments. Consequently, no storage lipid accumulates at the foveal pit. The underlying, highly vascular choroid and retinal pigment epithelium (RPE) remain unobstructed, transmitting their normal red-orange choroidal vascular hue, which appears strikingly red by contrast against the blanched surrounding retina.
3. Differential Diagnoses (Neurometabolic Storage Disorders):
   • Tay-Sachs disease (GM2 gangliosidosis type 1; B-variant)
   • Sandhoff disease (GM2 gangliosidosis type 2; 0-variant)
   • Niemann-Pick disease type A (acute neuropathic acid sphingomyelinase deficiency)
   • Farber lipogranulomatosis (acid ceramidase deficiency)
   • GM1 gangliosidosis type 1 (infantile generalized form)
   • Sialidosis type 1 / type 2 (Mucolipidosis I; neuraminidase deficiency)
   • Multiple sulfatase deficiency
4. Enzymatic and Genetic Profile of Tay-Sachs Disease:
   • Deficient Enzyme: $\beta$-Hexosaminidase A (isoenzyme A).
   • Defective Gene: HEXA gene located on chromosome 15q23 (encoding the $\alpha$-subunit of $\beta$-hexosaminidase A).

1. Inheritance Pattern:
   • Autosomal dominant inheritance (accounts for 75–80% of familial, non-syndromic cases; most commonly involving genes encoding crystalline lens proteins such as CRYAA, CRYBB2, or gap-junction proteins such as GJA8).
2. Metabolic, Infectious, and Systemic Etiologies:
   • Metabolic disorders: Classic galactosemia (galactose-1-phosphate uridylyltransferase deficiency) or galactokinase deficiency, Lowe oculocerebrorenal syndrome (OCRL gene), hypocalcemia, and sorbitol dehydrogenase deficiency.
   • Congenital intrauterine infections (TORCH): Congenital rubella syndrome, Cytomegalovirus (CMV), Toxoplasmosis, and Herpes simplex virus (HSV).
   • Chromosomal anomalies: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome).
3. Optimal Surgical Window:
   • 6 to 10 weeks of chronological age (optimally completed by 8 weeks of life to avert irreversible stimulus-deprivation amblyopia and infantile sensory nystagmus; unilateral dense cataracts require earlier intervention between 4 to 6 weeks of age).
4. Surgical Procedure and Refractive Strategy:
   • Surgical Technique: Lens aspiration (irrigation/aspiration or bimanual lensectomy) with primary posterior capsulorhexis (PPC) and limited anterior vitrectomy (via limbal or pars plicata approach to prevent visual axis opacification).
   • Primary Optical Rehabilitation: Leave the eye aphakic without primary intraocular lens (IOL) implantation (primary IOL is generally avoided under 6 months due to high rates of severe fibrinous uveitis, secondary capsular opacification, and unpredictable postoperative myopic shift).
   • Refractive Correction: Fit with aphakic silicone elastomeric extended-wear contact lenses or aphakic spectacles with bifocal add (+3.00 D near add), supplemented by structured amblyopia occlusion therapy.

1. Definitive Diagnosis:
   • Primary congenital glaucoma (infantile glaucoma / buphthalmos).
2. Pathophysiology of Symptom Triad:
   • Elevated Intraocular Pressure (IOP): Developmental dysgenesis of the trabecular meshwork and Schlemm's canal (trabeculodysgenesis with Barkan's membrane or high iris insertion) impairs aqueous humor outflow, markedly raising IOP.
   • Corneal Edema & Nerve Irritation: High IOP overcomes the endothelial fluid barrier and active endothelial pump, forcing fluid into the stroma and epithelium (microcystic epithelial edema).
   • Reflex Triad: Epithelial microcysts rupture and stretch corneal nerve terminals derived from the ophthalmic division of the trigeminal nerve (cranial nerve $V_1$), inciting trigeminal pain, reflex hyperlacrimation (epiphora), extreme light aversion (photophobia), and reflex spasmodic contraction of the orbicularis oculi muscle (blepharospasm).
3. Corneal Endothelial Breaks:
   • Haab Striae: Horizontal or curvilinear ruptures in Descemet's membrane caused by rapid corneal stretching under elevated IOP.
   • Significance: Serve as permanent objective evidence of prior high IOP; healed breaks can cause irregular astigmatism, corneal scarring, and acute corneal hydrops, predisposing to amblyopia.
4. Horizontal Corneal Diameters:
   • Normal Neonatal Value: $10.0\text{ to }10.5\text{ mm}$ (normal range: $9.5–10.5\text{ mm}$).
   • Abnormal Suspicion Cut-off:
     $$ > \text{Diameter} > 11.0\text{ mm in a newborn/neonate}, \quad \text{or} > 12.0\text{ mm in an infant } < 1\text{ year} > $$
     (or any inter-eye asymmetry $> 0.5\text{ mm}$).
5. Surgical Procedures of Choice:
   • Clear Cornea: Goniotomy (ab interno incision of the abnormal trabecular meshwork under direct gonioscopic visualization).
   • Opaque/Cloudy Cornea: Trabeculotomy ab externo (external canalization and unroofing of Schlemm's canal into the anterior chamber, eliminating the need for a clear optical view through the cornea). Combined trabeculotomy-trabeculectomy is preferred in refractory or advanced cases.

1. Most Probable Diagnosis:
   • Congenital / infantile subglottic hemangioma.
2. Radiographic Findings:
   • AP View of the Neck: Asymmetric, eccentric, smooth-bordered soft tissue narrowing of the subglottic trachea below the level of the true vocal cords (unlike the classic symmetric, tapered "steeple sign" of viral croup).
   • Lateral View of the Neck: Well-circumscribed, smooth, rounded or sessile soft-tissue mass projecting into the air column from the posterior or lateral wall of the subglottic lumen.
3. High-Risk Cutaneous Anatomical Distribution:
   • "Beard" distribution: Hemangiomas involving the mandibular area, chin, lower lip, preauricular regions, and anterior neck (distribution corresponding to the mandibular prominence / dermatome $V_3$).
4. First-Line Pharmacotherapy Protocol:
   • Drug & Route: Oral Propranolol solution.
   • Dosing Regimen:
     • Initiation: $1.0\text{ mg/kg/day}$ divided into 2 doses taken with or immediately after feeding.
     • Titration: If tolerated, titrate over 1–2 weeks to the target maintenance dose of $2.0\text{ to }3.0\text{ mg/kg/day}$ divided into two doses (every 12 hours).
     • Duration: Continued throughout the proliferative phase, usually until 12 to 18 months of age, followed by gradual tapering over 4–6 weeks to prevent rebound growth.
   • Mandatory Pre-Treatment Screening:
     • Baseline cardiovascular assessment: Heart rate, blood pressure, and a 12-lead electrocardiogram (ECG) to exclude bradycardia, second- or third-degree atrioventricular (AV) block, and congenital long-QT syndrome.
     • Screening for PHACE syndrome (cranial MRI/MRA and echocardiogram) if facial hemangioma is $>5\text{ cm}$ or plaque-like, to rule out coarctation of the aorta or cerebrovascular anomalies prior to $\beta$-blocker initiation.
     • Education on signs of drug-induced hypoglycemia and instruction never to administer propranolol during periods of prolonged fasting or acute gastroenteritis.

1. Unified Clinical Diagnosis:
   • Conjunctivitis-otitis syndrome (Otitis-conjunctivitis syndrome / Acute otitis media with purulent conjunctivitis).
2. Primary Bacterial Pathogen:
   • Non-typeable Haemophilus influenzae (NTHi) (responsible for $>70–80\%$ of conjunctivitis-otitis cases).
3. Other Common Bacterial Pathogens:
   • Streptococcus pneumoniae
   • Moraxella catarrhalis
   • (Staphylococcus aureus or Streptococcus pyogenes are occasional alternate pathogens).
4. Pathophysiological Linkage:
   • Pathogens initially colonize the mucosal surface of the nasopharynx.
   • Middle Ear Spread: Microorganisms ascend laterally and superiorly through the short, wide, and horizontal pediatric Eustachian tube into the middle ear cleft, provoking acute suppurative inflammation (acute otitis media).
   • Ocular Spread: Organisms ascend continuously via the nasolacrimal duct into the lacrimal sac and conjunctival sac, or are auto-inoculated directly from contaminated nasal secretions into the eye via the child's fingers (hand-to-eye transmission), leading to acute mucopurulent conjunctivitis.
5. First-Line Antimicrobial Regimen:
   • Drug: Oral Amoxicillin-Clavulanate (high-dose formulation; 14:1 or 7:1 ratio).
   • Weight-Based Dosing Calculation:
     $$ > \begin{aligned} > \text{Amoxicillin Component} &= \mathbf{80\text{ to }90\text{ mg/kg/day}} \\ > \text{Clavulanate Component} &= \mathbf{6.4\text{ mg/kg/day}} > \end{aligned} > $$
   • Route & Dosing Interval: Oral, divided twice daily (every 12 hours) with meals.
   • Duration: 10 days (standard duration for children $<5$ years with acute otitis media).
   • Pharmacological Rationale: High-dose amoxicillin alone is insufficient because 30% to 50% of non-typeable H. influenzae and almost $>90\%$ of M. catarrhalis isolates produce TEM-1 or ROB-1 $\beta$-lactamases, rendering standard amoxicillin ineffective. The addition of clavulanate, a $\beta$-lactamase inhibitor, restores full bactericidal coverage against $\beta$-lactamase-producing strains while the high-dose amoxicillin covers penicillin-intermediate S. pneumoniae.

1. Diagnostic Extraocular Motility Table:

   Muscle	Cranial Nerve Supply	Action in Abducted Position	Action in Adducted Position
   Lateral rectus	CN VI (Abducens)	Abduction	Minimal / ineffective abduction
   Medial rectus	CN III (Oculomotor, inferior division)	Minimal / ineffective adduction	Adduction
   Superior rectus	CN III (Oculomotor, superior division)	Pure elevation (visual axis aligns with muscle plane at $23^\circ$ abduction)	Intorsion (incyclotorsion) and adduction
   Inferior rectus	CN III (Oculomotor, inferior division)	Pure depression (visual axis aligns with muscle plane at $23^\circ$ abduction)	Extorsion (excyclotorsion) and adduction
   Superior oblique	CN IV (Trochlear)	Pure intorsion (incyclotorsion)	Pure depression (visual axis aligns with reflected tendon plane at $51^\circ\text{--}54^\circ$ adduction)
   Inferior oblique	CN III (Oculomotor, inferior division)	Pure extorsion (excyclotorsion)	Pure elevation (visual axis aligns with muscle line of pull at $51^\circ$ adduction)

2. Physiological Laws of Ocular Motility:

   • Hering's Law of Equal Innervation: Yoke muscles (contralateral synergists responsible for conjugate gaze in a given direction, e.g., right lateral rectus and left medial rectus for right lateral gaze) receive equal and simultaneous innervation.
   • Sherrington's Law of Reciprocal Innervation: Increased innervation and contraction of an agonist extraocular muscle is accompanied by a reciprocal, proportional relaxation and decreased innervation of its ipsilateral antagonist muscle (e.g., right medial rectus relaxes as right lateral rectus contracts).

3. Anatomical Basis of Superior Oblique Function:

   • The anatomical origin of the superior oblique is at the annulus of Zinn, but its functional origin is the fibrocartilaginous trochlea situated at the anteromedial aspect of the orbital roof.
   • The reflected tendon runs posterolaterally from the trochlea to insert into the posterolateral sclera behind the equator, forming an angle of approximately $51^\circ\text{--}54^\circ$ with the visual axis in the primary position.
   • When the eye is adducted by $51^\circ\text{--}54^\circ$, the visual axis becomes parallel to the line of pull of the reflected tendon, converting all force into pure downward vertical displacement (depression).

4. Parks-Bielschowsky Three-Step Test:

   • Step 1 (Primary Position): Determine which eye is hypertropic (e.g., right hypertropia indicates weakness of right depressors [right inferior rectus or right superior oblique] or left elevators [left superior rectus or left inferior oblique]).
   • Step 2 (Horizontal Gaze): Determine whether the hypertropia worsens on right or left lateral gaze (a right superior oblique palsy worsens on contralateral left gaze due to unopposed elevation of the right inferior oblique).
   • Step 3 (Bielschowsky Head Tilt): Determine whether the hypertropia worsens on right or left head tilt (a right superior oblique palsy worsens on ipsilateral right head tilt, because vestibular-ocular reflexes stimulate the ipsilateral intorters [right superior oblique and right superior rectus]; since the paralyzed superior oblique cannot intort, the superior rectus acts unopposed, elevating the right eye and exacerbating the hypertropia).

1. Chronological Progression of Auditory Localization Milestones:
   • Birth to 2 months: Startle response (Moro reflex) or blink (audito-palpebral reflex) to sudden loud sounds ($65\text{--}80\text{ dB}$); cessation of activity or widening of eyes to novel voices.
   • 3 to 4 months: Primitive horizontal head turning toward the sound source; rudimentary search behavior without consistent localization.
   • 5 to 6 months: Direct head turn horizontally toward the sound source on either side at ear level (lateral horizontal localization).
   • 6 to 8 months: Localizes sound laterally and then directs gaze vertically upward if the sound source is located above ear level (indirect vertical localization).
   • 9 to 10 months: Turns head directly and diagonally toward sound sources situated below or above the visual plane (direct diagonal/compound localization).
   • 10 to 12 months: Full direct localization to sound in any plane (horizontal, vertical, or diagonal) with prompt, precise head and eye orienting responses.
2. Auditory Startle Reflex (Audito-Palpebral and Moro Reflex):
   • Stimulus: Sudden, transient, intense acoustic stimulus ($70\text{--}90\text{ dB SPL}$).
   • Response: Rapid bilateral eyelid closure (auropalpebral reflex), accompanied by sudden abduction and extension of the upper extremities followed by flexion and crying (Moro reflex).
   • Extinction: Begins declining by 3 to 4 months and normally extinguishes by 4 to 6 months of age due to cortical maturation.
3. Behavioral Observation Audiometry (BOA) vs Visual Reinforcement Audiometry (VRA):
   • Behavioral Observation Audiometry (BOA):
     • Age range: Birth to 6 months (developmental age).
     • Methodology: Passive observation of unconditioned reflexive behavioral changes (e.g., eye widening, cessation of sucking, grimacing, body shift) in response to calibrated sounds presented in a sound field. Subjective, non-threshold test.
   • Visual Reinforcement Audiometry (VRA):
     • Age range: 6 months to 2.5 years (developmental age).
     • Methodology: Operant conditioning paradigm where the child is trained to turn toward an acoustic stimulus and is rewarded by an activated animated, illuminated visual toy located adjacent to the speaker/transducer. Yields reliable, frequency-specific hearing thresholds.
4. JCIH "1-3-6" Early Hearing Detection and Intervention (EHDI) Benchmarks:
   • 1 Month: Universal newborn hearing screening (UNHS) completed before hospital discharge or within 1 month of life using automated auditory brainstem response (A-ABR) or otoacoustic emissions (OAE).
   • 3 Months: Comprehensive diagnostic audiometric and medical evaluation completed by 3 months of age for all infants who fail/refer on the initial screen.
   • 6 Months: Initiation of early habilitative intervention, including hearing aid fitting, sensory devices, and communication therapy, no later than 6 months of age.

1. Diagnosis and Pathogen:
   • Clinical Diagnosis: Herpes Zoster Ophthalmicus (HZO).
   • Causative Organism: Varicella-Zoster Virus (VZV; Human alphaherpesvirus 3).
2. Neuroanatomical Pathomechanism and Eponymous Sign:
   • Pathomechanism: Reactivation of latent VZV residing within the trigeminal (Gasserian) ganglion following a primary varicella infection, with retrograde axonal transport along the ophthalmic division of the trigeminal nerve ($V_1$).
   • Hutchinson Sign: Presence of herpetic vesicles on the tip, ala, or side of the nose.
   • Anatomical Significance: The skin of the nasal tip is innervated by the external nasal branch of the nasociliary nerve (a terminal branch of $V_1$). Because the nasociliary nerve also supplies sensory innervation to the cornea, ciliary body, and iris, a positive Hutchinson sign confers an approximate 75% risk of concomitant intraocular inflammation and severe ocular complications.
3. Sight-Threatening Ocular Complications:
   • Neurotrophic keratopathy and corneal ulceration / perforation (due to corneal anesthesia).
   • Pseudodendritic epithelial keratitis, stromal keratitis, or disciform keratitis.
   • Acute anterior uveitis / iridocyclitis with secondary intraocular hypertension or glaucoma.
   • Acute retinal necrosis (ARN) or progressive outer retinal necrosis (PORN).
   • Trochlear, abducens, or oculomotor cranial nerve palsies; optic neuritis.
4. Pharmacological Management:
   • Systemic Antiviral (Immunocompromised Regimen):
     • Acyclovir: $10\text{--}15\text{ mg/kg/dose}$ IV every 8 hours (total $30\text{--}45\text{ mg/kg/day}$) administered by slow infusion over 1 hour.
     • Alternative oral step-down upon clinical stability: Oral acyclovir $20\text{ mg/kg/dose}$ (maximum $800\text{ mg/dose}$) 5 times daily.
     • Duration: 7 to 14 days minimum (or until all lesions are completely crusted and resolving).
   • Renal Protection: Hydrate aggressively with intravenous fluids during acyclovir infusion to prevent obstructive crystalline nephropathy.
   • Adjunctive Ophthalmic Therapy:
     • Preservative-free lubricating artificial tears and lubricating ointment.
     • Cyclopentolate 1% ophthalmic drops (1 drop 2–3 times daily) if ciliary spasm or anterior chamber cells are present.
     • Topical ophthalmic corticosteroids (e.g., prednisolone acetate 1%) only after excluding active epithelial keratitis and under direct supervision of an ophthalmologist.

1. Diagnosis and Causative Pathogen:

   • Diagnosis: Acute External Hordeolum (Stye).
   • Causative Pathogen: Staphylococcus aureus (responsible for >90% of cases).

2. External vs Internal Hordeolum:

   Feature	External Hordeolum	Internal Hordeolum
   Glandular Structure	Infection of the Glands of Zeis (sebaceous) or Glands of Moll (apocrine sweat glands) associated with the lash follicle	Infection of the Meibomian glands situated within the tarsal plate
   Anatomical Plane	Superficial to the tarsal plate	Deep, within the dense fibrous tarsal plate
   Direction of Pointing	Points outward toward the external skin margin at the base of an eyelash	Points inward toward the palpebral conjunctiva (eversion of lid reveals focal tarsal abscess)

3. Differentiation from Chalazion:

   Feature	Hordeolum	Chalazion
   Pathology	Acute suppurative bacterial microabscess	Chronic, non-infectious, sterile lipogranulomatous inflammatory reaction
   Pain / Tenderness	Marked pain, exquisite focal tenderness, warm, erythematous	Typically painless, non-tender, cold, firm nodule
   Onset & Natural History	Acute onset (1–3 days); rapid suppuration with pointing	Indolent onset (weeks to months); slow progressive growth
   Gland Origin	Glands of Zeis/Moll (external) or Meibomian (internal)	Exclusively Meibomian gland duct obstruction

4. Management Protocol:

   • Conservative Therapy:
     • Frequent warm compresses: Clean, warm, moist washcloth applied to closed eyelids for 10 to 15 minutes, 3 to 4 times daily to facilitate spontaneous drainage.
     • Strict eyelid hygiene; instruction to avoid squeezing or manual popping of the lesion.
   • Topical Antibiotics:
     • Indicated if purulent discharge or secondary blepharitis is present: Tobramycin 0.3% ophthalmic ointment or Moxifloxacin 0.5% ophthalmic drops applied to the conjunctival sac 3 to 4 times daily for 5 to 7 days.
   • Systemic Antibiotics:
     • Indicated if preseptal cellulitis develops: Oral Co-amoxiclav ($45\text{ mg/kg/day}$ of amoxicillin component divided every 12 hours) or Cefalexin ($50\text{ mg/kg/day}$ divided every 6–8 hours) for 7 days.
   • Surgical Intervention:
     • Indication: Large, fluctuant abscess failing to drain spontaneously after 48–72 hours of conservative therapy.
     • Technique for External Hordeolum: Removal/epilation of the involved eyelash follicle, or stab incision placed horizontally (parallel to eyelid margin and natural skin creases) to avoid scar contracture.
     • Technique for Internal Hordeolum: Incision placed vertically (perpendicular to lid margin) through the conjunctival surface of the everted tarsal plate to avoid transecting adjacent Meibomian gland ducts.

1. Inheritance and Molecular Genetics:
   • Congenital Cataract: Most common familial pattern is Autosomal Dominant (AD) (~75% of non-syndromic hereditary cases); remaining are Autosomal Recessive (AR) or X-linked. Key genes: CRYAA, CRYBB2 (crystallins), GJA3, GJA8 (connexins), and MIP (aquaporin-0).
   • Retinitis Pigmentosa (RP): Marked genetic heterogeneity:
     • Autosomal Recessive (AR): 50–60% of familial cases (genes: USH2A, RPE65, PDE6A).
     • Autosomal Dominant (AD): 30–40% (genes: RHO [rhodopsin], PRPF31).
     • X-linked Recessive (XLR): 10–15% (genes: RPGR, RP2).
   • Primary Congenital Glaucoma (PCG): Primarily Autosomal Recessive (AR) (~10–40% familial; higher in consanguineous populations; sporadic in non-consanguineous cohorts). Key gene: CYP1B1 (cytochrome P450 family 1 subfamily B member 1); less commonly LTBP2.
   • Retinoblastoma (RB): Autosomal Dominant with high penetrance (~90%) at the organismal level; recessive at the cellular level. Gene: RB1 tumor suppressor gene located at chromosome 13q14.2.
2. Knudson's Two-Hit Hypothesis:
   • Heritable Retinoblastoma (~40% of all cases):
     • First Hit: Germline mutation present in all somatic cells (inherited from an affected parent [25%] or arising de novo in parental gamete [75%]).
     • Second Hit: Somatic mutation or loss of heterozygosity (LOH) in a developing retinal cell (retinoblast).
     • Phenotype: Bilateral (85%), multifocal, early age of onset (median ~12 months), elevated lifetime risk of non-ocular second primary neoplasms (osteosarcoma, soft tissue sarcoma, pineoblastoma ["trilateral retinoblastoma"]).
   • Non-Heritable Retinoblastoma (~60% of all cases):
     • Both Hits: Two independent, sequential somatic mutational events occurring exclusively within a single retinal precursor cell.
     • Phenotype: Strictly unilateral, unifocal, later onset (median ~24 months), no elevated risk of secondary primary malignancies, offspring have population baseline risk (<1%).
3. Primary Congenital Glaucoma (PCG) Features:
   • Classic Diagnostic Triad:
     • Epiphora (excessive tearing)
     • Photophobia (light sensitivity)
     • Blepharospasm (involuntary eyelid closure)
   • Associated Sign: Buphthalmos ("ox eye" with enlarged corneal diameter $>12\text{ mm}$ in infants $<1$ year) and Haab striae (breaks in Descemet's membrane).
   • Genetics in India: Pathogenic mutations in the CYP1B1 gene located on chromosome 2p22.2–p21 account for up to 40% to 50% of PCG cases in consanguineous Indian pedigrees.
4. Surveillance Protocol for Carrier of RB1 Germline Mutation:
   • Baseline Examination: Comprehensive dilated fundoscopic examination under anesthesia (EUA) by a pediatric ocular oncologist within the first 1–2 weeks of life.
   • Frequency of Dilated Indirect Ophthalmoscopy under Anesthesia (EUA):
     • 0 to 12 months: Every 3 to 4 weeks.
     • 1 to 2 years: Every 6 to 8 weeks.
     • 2 to 3 years: Every 3 months.
     • 3 to 5 years: Every 4 to 6 months.
     • 5 to 7 years: Every 6 months, transitioning to awake examinations if cooperative.
   • Neuroimaging Surveillance: Brain MRI without and with intravenous contrast every 6 months until age 5 years to screen for trilateral retinoblastoma (pinealoblastoma or suprasellar neuroectodermal tumors). Avoid cranial CT scans to eliminate ionizing radiation exposure in this radiosensitive population.

1. Clinical Finding & Location:
   • Iris coloboma of the right eye.
   • Classical location: Typically located in the inferonasal quadrant of the iris (keyhole or pear-shaped pupil).
2. Associated Conditions:
   • Congenital systemic conditions:
     • CHARGE syndrome (CHD7 mutation: Coloboma, Heart defects, Atresia choanae, Retarded growth, Genital hypoplasia, Ear abnormalities)
     • Cat eye syndrome (Chromosome 22 partial tetrasomy)
     • Patau syndrome (Trisomy 13)
     • Treacher Collins syndrome
   • Acquired conditions:
     • Ocular trauma (penetrating or severe blunt trauma causing iridodialysis/iris tear)
     • Prior intraocular surgery (surgical peripheral or optical iridectomy)
3. Embryological Basis:
   • Results from the defective or incomplete fusion of the embryonic optic (choroidal) fissure during the 5th to 7th week of embryonic development (specifically day 33 to 40 of gestation).
   • Because the optic fissure closes from the equator forward toward the pupillary margin, failure of the most anterior closure results in an isolated iris coloboma, whereas extensive non-closure causes chorioretinal, ciliary body, and optic disc colobomas.
4. Clinical Symptoms & Visual Complications:
   • Photophobia and glare: Inability of the defective iris to constrict effectively, resulting in excessive light entry and optical aberrations.
   • Refractive errors and astigmatism: Irregular corneal or lenticular curvature.
   • Visual field defects: If associated with posterior chorioretinal involvement (superior visual field scotoma).
   • Deprivation amblyopia: Due to uncorrected refractive errors, anisometropia, or associated microphthalmos/cataract.

1. Clinical Diagnosis:
   • Congenital laryngomalacia.
2. Diagnostic Modality & Endoscopic Findings:
   • Gold standard: Awake flexible fiberoptic laryngoscopy (FFL) via transnasal route.
   • Dynamic endoscopic findings on inspiration:
     • Elongated, tubular, curled epiglottis folding upon itself (omega-shaped [$\Omega$] epiglottis).
     • Shortened aryepiglottic folds tethering the epiglottis posteriorly.
     • Inward collapse/prolapse of redundant supra-arytenoid cartilaginous tissue (arytenoids, corniculate, and cuneiform) into the laryngeal inlet during inspiration.
3. Grading & Indications for Surgery:
   • Clinical grading:
     • Mild: Inspiratory stridor only; thriving infant, absent or minimal retractions; no feeding difficulties.
     • Moderate: Stridor with feeding cough/choking, mild-to-moderate retractions; thriving maintained.
     • Severe: Failure to thrive, severe retractions (pectus excavatum), recurrent cyanosis/apnea, cor pulmonale.
   • Indications for surgical intervention:
     • Failure to thrive / weight loss secondary to increased work of breathing and feeding difficulty.
     • Severe airway compromise with resting oxygen desaturations, recurrent cyanosis, or life-threatening apnea.
     • Subglottic/tracheal architectural remodeling (progressive pectus excavatum).
     • Recurrent aspiration pneumonia or development of cor pulmonale / pulmonary hypertension.
4. Definitive Surgery & Medical Co-therapy:
   • Definitive surgical procedure: Supraglottoplasty (microsurgical or cold-knife/laser division of shortened aryepiglottic folds and excision of redundant cuneiform/arytenoid mucosa).
   • Concurrent medical co-therapy: Aggressive anti-reflux medical therapy (Proton pump inhibitor, e.g., Esomeprazole 1 mg/kg/day, or H2 receptor antagonist) due to the near-universal co-occurrence of gastroesophageal reflux disease (GERD) exacerbating mucosal edema.

1. Screening Examination Technique & Protocol:
   • Technique: Red reflex examination (Bruckner test).
   • Performance protocol:
     • Conducted in a darkened or dimly lit room to facilitate physiological pupillary dilation.
     • The examiner uses a direct ophthalmoscope set at lens power "0" (or matched to the examiner's refractive error).
     • Positioned at a distance of approximately 18 to 20 inches (45 to 50 cm) from the infant's face.
     • Both pupils are illuminated and viewed simultaneously to evaluate the color, brightness, and symmetry of the fundal reflection.
2. Interpretation:
   • Left eye: Normal, bright, homogeneous orange-red fundal reflex.
   • Right eye: Leukocoria (white pupillary reflex / amaurotic cat's eye reflex) characterized by complete absence of the normal red-orange reflex, replaced by an abnormal white-yellow intraocular reflection.
3. Differential Diagnosis of Leukocoria:
   • Retinoblastoma (most common life-threatening intraocular malignancy in infancy)
   • Congenital cataract
   • Persistent Fetal Vasculature (PFV) / Persistent Hyperplastic Primary Vitreous (PHPV)
   • Advanced Retinopathy of Prematurity (Stage 4 or 5 ROP with retinal detachment)
   • Coats disease (retinal telangiectasia with exudative retinal detachment)
   • Ocular toxocariasis (granulomatous endophthalmitis)
4. Triage Pathway & Bedside Investigation:
   • Immediate triage: Urgent same-week referral to a pediatric ophthalmologist / ocular oncologist for examination under anesthesia (EUA) with indirect ophthalmoscopy.
   • Initial non-invasive bedside investigation: B-scan ocular ultrasonography (USG eye) to evaluate for intraocular calcification, acoustic shadowing (hallmark of retinoblastoma), and structural retinal detachment.

1. Clinical Diagnosis:
   • Microbial keratitis / corneal ulcer with secondary hypopyon.
2. Common Bacterial Pathogens:
   • Pseudomonas aeruginosa
   • Staphylococcus aureus (including Methicillin-resistant S. aureus [MRSA])
   • Streptococcus pneumoniae
3. Bedside Diagnostic Test & Expected Finding:
   • Procedure: Fluorescein dye staining examination under cobalt blue filter illumination (using a slit lamp or Burton lamp).
   • Expected finding: Intense, bright apple-green fluorescence over the area of denuded corneal epithelium outlining the exact margins of the ulcer bed, with surrounding yellowish-green stromal pooling.
4. Vision-Threatening Complications:
   • Corneal stromal melting and perforation with iris prolapse
   • Endophthalmitis or panophthalmitis leading to phthisis bulbi
   • Secondary closed-angle glaucoma due to peripheral anterior synechiae formation
   • Dense corneal leukoma / scarring causing permanent deprivation amblyopia
5. Empiric Antimicrobial Regimen & Contraindicated Drug:
   • Empiric topical antimicrobial regimen:
     • Dual fortified topical broad-spectrum antibiotic drops: Fortified Cefazolin (50 mg/mL, 5%) OR Fortified Vancomycin (50 mg/mL, 5%) PLUS Fortified Tobramycin (14 mg/mL, 1.4%) OR Amikacin (25 mg/mL, 2.5%).
     • Dosing frequency: 1 drop into the affected eye every 30 to 60 minutes around the clock for the first 24 to 48 hours, then tapered based on clinical response and corneal scraping cultures.
     • Alternative monotherapy: Topical fluoroquinolone (Moxifloxacin 0.5% or Gatifloxacin 0.3%) 1 drop hourly.
   • Strictly contraindicated medication: Topical corticosteroids (e.g., Prednisolone, Dexamethasone), as they suppress host immunity, accelerate collagenase-mediated stromal melting, promote corneal perforation, and potentiate fungal superinfections.

1. Clinical Pathology:
   • Bilateral nasal polyposis (ethmoidal nasal polyps).
2. Primary Etiology & Gold Standard Test:
   • Underlying condition: Cystic Fibrosis (autosomal recessive mutation in the CFTR gene).
   • Gold standard confirmatory test: Quantitative pilocarpine iontophoresis sweat test (sweat chloride concentration $\ge 60\text{ mmol/L}$ on two separate occasions) supplemented by CFTR gene mutation analysis.
3. Additional Clinical Associations:
   • Allergic Fungal Rhinosinusitis (AFRS)
   • Aspirin-Exacerbated Respiratory Disease (AERD / Samter triad: asthma, nasal polyps, and NSAID hypersensitivity)
   • Primary Ciliary Dyskinesia (PCD / Kartagener syndrome)
   • Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss syndrome)
4. Distinction from Inferior Turbinate:
   • Tactile sensation: Nasal polyps are completely insensitive/painless to gentle probing with a blunt probe; turbinates are exquisitely sensitive and tender.
   • Mobility and consistency: Polyps are soft, mobile, and easily compressed/displaced; turbinates are firm, fixed to the lateral nasal wall, and non-mobile.
   • Vascularity / Response to vasoconstrictor: Polyps are avascular, pale-gray/yellowish, glistening, do not bleed on gentle touch, and do not shrink with topical vasoconstrictors (e.g., oxymetazoline); turbinates are pink-erythematous, bleed easily, and visibly shrink following topical decongestant application.
5. Pharmacological Management & Definitive Surgery:
   • Pharmacological therapy:
     • First-line: Intranasal corticosteroid spray (Mometasone furoate 50 mcg/actuation or Fluticasone propionate 50 mcg/actuation: 1 spray in each nostril once daily for children 2-11 years; 2 sprays once daily for $\ge 12$ years) for at least 8 to 12 weeks.
     • High-volume isotonic or hypertonic nasal saline irrigations twice daily.
     • Short course of systemic oral corticosteroids (Prednisolone 1 mg/kg/day, maximum 40 mg/day, for 10-14 days with taper) for severe obstructive polyposis.
   • Surgical indication & procedure: Indicated when there is complete nasal airway obstruction, facial skeletal remodeling, or failure of medical therapy after 8-12 weeks; the procedure of choice is Functional Endoscopic Sinus Surgery (FESS) with endoscopic microdebrider polypectomy.

1. Identification and Anatomical Landmarks:
   • Laterality: Right tympanic membrane (manubrium points posterosuperiorly, cone of light is in the anteroinferior quadrant).
   • Key landmarks:
     • Pars tensa (translucent, pearly-gray surface)
     • Pars flaccida (Shrapnell's membrane, located superiorly)
     • Lateral (short) process of the malleus
     • Handle (manubrium) of the malleus
     • Umbo (central depression at the tip of the manubrium)
     • Cone of light (light reflex directed anteroinferiorly toward the 5 o'clock position)
     • Anterior and posterior malleolar folds
2. Quadrants and Surgical Site:
   • Quadrants: Divided by an imaginary line running along the handle of the malleus and a perpendicular line passing through the umbo:
     • Anterosuperior (AS)
     • Anteroinferior (AI)
     • Posterosuperior (PS)
     • Posteroinferior (PI)
   • Safest site for myringotomy: Anteroinferior quadrant (or posteroinferior quadrant). The anteroinferior quadrant avoids injury to the ossicular chain (incus, stapes), the chorda tympani nerve, and the round window niche located in the posterosuperior quadrant.
3. Procedural Checklist for Pneumatic Otoscopy:
   • Positioning: Seat the child comfortably on the caregiver's lap or supine; brace the examining hand firmly against the child's cheek/zygoma to prevent canal laceration from sudden head movements.
   • Speculum selection: Choose the largest speculum diameter that fits snugly into the external auditory canal to create an airtight seal.
   • Canal straightening: Pull the pinna posterosuperiorly (for children $>3$ years) or posteroinferiorly (for infants/toddlers $<3$ years).
   • Insufflation: Gently compress the pneumatic bulb to apply positive pressure, then release to create negative pressure while continuously observing membrane excursion.
4. Physiological Response and Pathophysiology:
   • Normal response: Crisp, symmetrical inward and outward mobility of the pars tensa upon positive and negative pressure application.
   • Abnormal response (hypomobility/immobility): Signifies altered middle ear compliance due to middle ear effusion (otitis media with effusion), hemotympanum, acute suppurative otitis media, tympanosclerosis, adhesive otitis, or marked negative middle ear pressure caused by Eustachian tube dysfunction.

1. Phenotypic Matching:
   • (A) Kayser-Fleischer rings: Wilson disease (hepatolenticular degeneration; copper deposition in Descemet's membrane).
   • (B) Cherry-red macular spot: GM2 gangliosidosis (Tay-Sachs disease, Sandhoff disease) / Niemann-Pick disease type A.
   • (C) Kinky, brittle hair: Menkes disease (kinky hair syndrome; impaired copper transport via ATP7A mutation).
   • (D) Arcus juvenilis: Familial hypercholesterolemia (type IIa hyperlipidemia; corneal stromal lipid deposition).
2. Pathophysiology of Cherry-Red Spot:
   • Retinal ganglion cells (RGCs) are multi-layered and densely concentrated in the perifoveal macula, while the central fovea contains only photoreceptors and lacks ganglion cells.
   • In storage disorders (e.g., GM2 gangliosidoses, Niemann-Pick), intralysosomal accumulation of undigested lipids/sphingolipids causes swelling, opacification, and pallor of the surrounding perifoveal RGC layers.
   • The unobstructed red color of the highly vascularized choroid shines through the thin, avascular central fovea, creating the stark contrast seen as a "cherry-red spot."
3. Mathematical Derivation:
   $$ > \begin{aligned} > \text{Free Serum Copper } (\mu\text{g/dL}) &= \text{Total Copper } (\mu\text{g/dL}) - [3 \times \text{Ceruloplasmin } (\text{mg/dL})] \\ > &= 70 - [3 \times 15] \\ > &= 70 - 45 \\ > &= \mathbf{25\ \mu\text{g/dL}} \quad (\text{Reference Range: } < 10\text{–}15\ \mu\text{g/dL}) > \end{aligned} > $$
   • Interpretation: A level of $25\ \mu\text{g/dL}$ is elevated (abnormal $>15\ \mu\text{g/dL}$), corroborating elevated free circulating copper and supporting the diagnosis of Wilson disease.
4. Pharmacotherapy and Management:
   • Chelation therapy:
     • D-Penicillamine: $20\ \text{mg/kg/day}$ orally in 2 to 3 divided doses administered 1 hour before or 2 hours after meals (titrated gradually up to maximum $1000\text{–}1500\ \text{mg/day}$).
     • Alternative chelator: Trientine dihydrochloride ($20\ \text{mg/kg/day}$ divided BID or TID).
     • Pyridoxine supplementation: $25\text{–}50\ \text{mg/day}$ orally concurrently with penicillamine to prevent drug-induced vitamin B6 deficiency.
   • Maintenance/Absorption blocking:
     • Elemental Zinc (acetate or gluconate): $25\text{–}50\ \text{mg}$ elemental zinc BID or TID orally (competes with copper for intestinal metallothionein absorption).
   • Dietary modification: Strict restriction of copper-rich foods (organ meats, shellfish, mushrooms, nuts, chocolate).

1. Fundus Description and Diagnosis:
   • Description: Diffuse, chalky-white (or porcelain-white) pallor of the optic nerve head, loss of normal microvascular network (Kestenbaum's sign: reduced small disc vessels), attenuation and thinning of retinal arterioles, and preservation of clear lamina cribrosa fenestrations.
   • Diagnosis: Optic atrophy (optic nerve pallor).
2. Etiology in Children:
   • Primary causes (descending/retrobulbar pathology):
     • Intracranial/chiasmatic tumors: Craniopharyngioma, optic pathway glioma (neurofibromatosis type 1), hypothalamic astrocytoma.
     • Hereditary optic neuropathies: Leber hereditary optic neuropathy (LHON - mitochondrial), Autosomal dominant optic atrophy (ADOA - OPA1 gene).
   • Secondary causes (consecutive or post-papilledema):
     • Chronic raised intracranial pressure: Obstructive hydrocephalus (e.g., aqueductal stenosis), untreated idiopathic intracranial hypertension (pseudotumor cerebri).
     • Post-inflammatory/post-infectious: Resolved optic neuritis (e.g., MOG-antibody disease, neuromyelitis optica spectrum disorder), tubercular or bacterial meningoencephalitis.
3. Ophthalmoscopic Differentiation:
   • Primary Optic Atrophy:
     • Disc Color: Chalky-white or porcelain-white with discrete loss of neuroretinal rim.
     • Disc Margins: Sharply demarcated and well-defined.
     • Physiological Cup: Preserved, deep cup; lamina cribrosa pores distinctly visible.
     • Surrounding Retina/Vessels: Normal peripapillary retina; vessel caliber may be narrowed without perivascular sheathing.
   • Secondary (Post-Papilledema) Optic Atrophy:
     • Disc Color: Dirty-gray or yellowish-white hue due to reactive gliosis.
     • Disc Margins: Irregular, hazy, blurred, and poorly defined.
     • Physiological Cup: Obliterated and filled with proliferative glial tissue; lamina cribrosa obscured.
     • Surrounding Retina/Vessels: Perivascular cuffing/sheathing, tortuosity, and residual pigmentary disturbances around the disc margin.
4. Diagnostic Workup:
   • Neuroimaging: High-resolution contrast-enhanced MRI of the brain and orbits with fat-suppressed T1 sequences and thin ($2\text{ mm}$) coronal cuts through the optic nerves and chiasm to identify compressive masses, intrinsic nerve gliomas, or demyelinating lesions.
   • Visual Evoked Potentials (VEP): Flash and pattern-reversal VEP to assess optic pathway conduction velocity (delayed P100 wave latency denotes demyelination; reduced P100 wave amplitude denotes axonal loss).
   • Optical Coherence Tomography (OCT): Quantitative measurement of retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness to objectively quantify axonal loss.
   • Visual Field Testing: Age-appropriate automated perimetry (e.g., Humphrey visual fields) to delineate visual deficits (e.g., bitemporal hemianopia in chiasmatic compression, central scotoma in optic neuritis).

1. Radiological Findings and Diagnosis:
   • CT Findings: Complete opacification of the ipsilateral (right) ethmoid air cells and maxillary sinus with mucosal thickening, accompanied by a well-demarcated subperiosteal hypodense fluid collection with peripheral ring enhancement along the medial orbital wall, causing lateral displacement of the medial rectus muscle and proptosis of the globe.
   • Diagnosis: Orbital cellulitis with subperiosteal abscess (SPA) secondary to acute ethmoid sinusitis.
2. Chandler Classification:
   • Stage I: Preseptal cellulitis (edema anterior to the orbital septum).
   • Stage II: Orbital cellulitis (diffuse postseptal infiltration without discrete abscess).
   • Stage III: Subperiosteal abscess (collection between the orbital periorbita/periosteum and the bony lamina papyracea) — Current Stage.
   • Stage IV: Orbital abscess (collection within the intra- or extra-conal orbital fat).
   • Stage V: Cavernous sinus thrombosis (retrograde intracranial extension).
3. Anatomical Route and Microbiological Profile:
   • Anatomical route: Direct extension from adjacent ethmoid air cells through the paper-thin, naturally dehiscent lamina papyracea, or retrograde thrombophlebitic spread via the valveless ophthalmic venous system (veins of Breschet).
   • Common pathogens:
     • Streptococcus pneumoniae
     • Streptococcus anginosus group (S. intermedius, S. constellatus)
     • Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA])
     • Non-typeable Haemophilus influenzae
     • Anaerobes (Peptostreptococcus, Fusobacterium, Bacteroides species, particularly in children $>9$ years)
4. Therapeutic Protocol and Surgical Indications:
   • Empirical IV Antimicrobial Therapy:
     • Ceftriaxone: $100\ \text{mg/kg/day}$ IV divided q12h (or Cefotaxime $200\ \text{mg/kg/day}$ IV divided q6h) plus
     • Vancomycin: $60\ \text{mg/kg/day}$ IV divided q6h (for MRSA coverage; target trough $15\text{–}20\ \mu\text{g/mL}$) plus
     • Metronidazole: $30\ \text{mg/kg/day}$ IV divided q8h (for anaerobic coverage).
   • Absolute Surgical Indications for Drainage:
     • Impending vision loss: Visual acuity drop, persistent relative afferent pupillary defect (RAPD), or elevated intraocular pressure ($>20\text{–}25\ \text{mmHg}$).
     • Large abscess volume: Subperiosteal collection width $>10\ \text{mm}$ or volume $>0.5\text{–}1.0\ \text{mL}$.
     • Lack of clinical improvement or deterioration after $24\text{–}48\ \text{hours}$ of targeted IV antibiotics.
     • Non-medial abscess location (superior or lateral subperiosteal abscess).
     • Concomitant intracranial extension or signs of cavernous sinus thrombosis.

1. Otoscopic Interpretation and Diagnosis:
   • Preoperative finding: Dull, retracted, amber-to-gray tympanic membrane with prominent lateral process of the malleus, foreshortened handle of malleus, loss of the normal cone of light, and visible air-fluid levels/effusion bubbles behind the pars tensa.
   • Diagnosis: Otitis Media with Effusion (OME; chronic serous otitis media or "glue ear").
2. Mathematical Calculation of Air-Bone Gap (ABG):
   $$
   \begin{aligned

1. Funduscopic Findings:
   • Marked hyperemic elevation of the optic nerve head (optic disc)
   • Complete blurring and obscuration of the optic disc margins
   • Loss of the central physiological cup
   • Engorgement, tortuosity, and dilation of the retinal veins with obscuration of major retinal vessels crossing the disc boundary
   • Peripapillary flame-shaped hemorrhages, cotton-wool spots (nerve fiber layer infarcts), and absence of spontaneous venous pulsations
2. Diagnosis and Grading Scheme:
   • Definitive Diagnosis: Papilledema (bilateral optic disc edema secondary to raised intracranial pressure [ICP])
   • Grading Classification: Modified Frisén Scale (Grades 0 to 5, ranging from minimal C-shaped halo to severe dome-shaped protrusion with total vessel obscuration)
3. Etiological Categorization:
   • Intracranial mass lesions / space-occupying lesions: Medulloblastoma, astrocytoma, ependymoma, brain abscess, tuberculoma
   • Disorders of CSF dynamics (Hydrocephalus): Aqueductal stenosis, Dandy-Walker malformation, post-meningitic basal cisternal adhesions
   • Impaired venous drainage: Cerebral venous sinus thrombosis (CVST secondary to dehydration, mastoiditis, or prothrombotic states)
   • Idiopathic / Toxic-Metabolic: Idiopathic intracranial hypertension (Pseudotumor cerebri), hypervitaminosis A, all-trans retinoic acid therapy, tetracycline/minocycline toxicity, systemic corticosteroid withdrawal
4. Distinction Between Acute vs. Chronic Optic Disc Edema:
   • Acute disc edema: Hyperemic, pink/red disc, prominent splinter hemorrhages, exudates/cotton-wool spots, dilated tortuous vessels, preserved visual acuity and color vision initially.
   • Chronic/Atrophic disc edema: Pale, chalky-white or gray disc (secondary optic atrophy), absent hemorrhages and cotton-wool spots, presence of optociliary shunt vessels (retinochoroidal collaterals), severely constricted peripheral visual fields, and marked decline in visual acuity.
5. Mandatory Neuroimaging Prior to Lumbar Puncture:
   • Modality: Magnetic Resonance Imaging (MRI) of the brain with contrast and Magnetic Resonance Venography (MRV).
   • Rationale: To rule out an intracranial space-occupying lesion, midline shift, structural hydrocephalus, or impending transtentorial/tonsillar herniation; performing a lumbar puncture in the presence of an obstructive intracranial mass creates a downward pressure gradient precipitating fatal brainstem coning.
6. Pharmacotherapy for Intracranial Hypertension:
   • Acetazolamide: Oral, $25\text{ to }50\text{ mg/kg/day}$ divided every $8\text{ to }12\text{ hours}$ (starting at $15\text{ to }25\text{ mg/kg/day}$ and titrating upwards; maximum dose: $2{,}000\text{ mg/day}$ or $2\text{ g/day}$).
   • Adjuvant (if refractory or poor tolerance): Furosemide $1\text{ mg/kg/day}$ orally or Topiramate $1.5\text{ to }3\text{ mg/kg/day}$ divided every 12 hours.

1. Clinical Diagnosis:
   • Pediatric Obstructive Sleep Apnea Syndrome (OSAS).
2. Predisposing Factors:
   • Structural/Anatomical:
     • Adenotonsillar hypertrophy (most frequent etiology)
     • Craniofacial dysmorphism (retrognathia, micrognathia, midface hypoplasia as in Pierre Robin sequence, Crouzon syndrome, or Treacher Collins syndrome)
     • Severe septal deviation, nasal polyposis, or inferior turbinate hypertrophy
     • Obesity-related parapharyngeal adipose tissue deposition
     • Macroglossia (e.g., Beckwith-Wiedemann syndrome)
   • Neuromuscular/Genetic:
     • Down syndrome (Trisomy 21) due to combined generalized hypotonia, hypoplastic midface, and lingual enlargement
     • Neuromuscular disorders (Duchenne muscular dystrophy, spinal muscular atrophy, cerebral palsy) resulting in pharyngeal dilator collapsibility
     • Achondroplasia (craniocervical junction constriction and midface hypoplasia)
3. Gold-Standard Diagnostic Modality & Criteria:
   • Gold Standard: Overnight in-laboratory Polysomnography (Level 1 PSG).
   • Pediatric Diagnostic Criteria (AHI / OAHI):
     • Normal: $\text{AHI} < 1\text{ event/hour}$
     • Mild OSAS: $\text{AHI } 1.0\text{ to }4.9\text{ events/hour}$
     • Moderate OSAS: $\text{AHI } 5.0\text{ to }9.9\text{ events/hour}$
     • Severe OSAS: $\text{AHI } \ge 10.0\text{ events/hour}$ (or oxygen saturation nadir $< 80\%$)
4. Long-Term Complications:
   • Neurocognitive/Behavioral:
     • Attention-deficit/hyperactivity disorder (ADHD) phenotypic manifestations
     • Executive function impairment and academic failure
     • Daytime hypersomnolence, mood lability, and aggressive behavior
     • Growth failure / failure to thrive (due to nocturnal growth hormone suppression and increased work of breathing)
   • Cardiopulmonary:
     • Pulmonary arterial hypertension and Cor Pulmonale (secondary to chronic nocturnal alveolar hypoxia and hypercapnia)
     • Systemic arterial hypertension (secondary to recurrent autonomic sympathetic surges)
     • Left ventricular hypertrophy and endothelial dysfunction
5. Therapeutic Interventions:
   • First-line Surgical Intervention: Adenotonsillectomy (T&A).
   • Non-surgical / Conservative Management:
     • Intranasal corticosteroids (e.g., Fluticasone furoate $27.5\text{ mcg/spray}$, 1 spray/nostril once daily or Mometasone furoate $50\text{ mcg/spray}$, 1 spray/nostril once daily) combined with oral Montelukast ($5\text{ mg}$ once daily at night) for mild OSAS.
     • Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) titration for surgical non-candidates or persistent post-surgical OSAS.
     • Orthodontic rapid maxillary expansion (for high-arched, narrow hard palates) and weight reduction programs in obese adolescents.

1. Normal Visual Acuity by Chronological Age:
   • 3 months: $6/60\text{ to }6/120$ ($20/200\text{ to }20/400$)
   • 12 months: $6/18\text{ to }6/30$ ($20/60\text{ to }20/100$)
   • 3 years: $6/12$ ($20/40$)
   • 4 years: $6/9$ ($20/30$)
   • 5 to 6 years: $6/6$ ($20/20$ adult equivalent)
2. Age-Appropriate Visual Acuity Testing Modalities:
   • Preverbal infants ($< 2$ years):
     • Teller Acuity Cards (Preferential Looking Test using square-wave gratings)
     • Cardiff Acuity Cards (vanishing optotypes)
     • Fixation and Following behavior (CSM method: Central, Steady, Maintained)
     • Pattern Visual Evoked Potentials (p-VEP)
   • Preschool children ($3\text{ to }4$ years):
     • LEA Symbols chart (circle, square, apple, house)
     • HOTV matching optotype chart
     • Tumbling E chart
   • School-aged cooperative children ($\ge 5$ years):
     • Standard Snellen letter or number chart
     • Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR letter chart
3. Visual Milestones from Birth to 6 Months:
   • Birth to 4 weeks: Rudimentary pupillary light reflex; transient blink to sudden bright light; fixes transiently on high-contrast, large targets at 20–30 cm.
   • 6 to 8 weeks: Consistent central fixation established; social smile in response to maternal facial contact.
   • 2 to 3 months: Smooth horizontal pursuit tracking up to $180^\circ$; reaches toward visually identified objects.
   • 4 to 6 months: Full smooth vertical and horizontal ocular pursuit; emergence of functional binocular stereopsis (depth perception); transient physiologic intermittent strabismus resolves (any misalignment after 4 months is pathological).
4. Critical Period and Sequelae:
   • Definition: The plastic window of neurodevelopment (extending from birth to approximately 7–8 years of age) during which the visual cortex requires clear, focused, symmetric retinal stimulation to establish normal synaptic connectivity in the lateral geniculate body and visual cortex (Brodmann area 17).
   • Irreversible Sequelae:
     • Permanent stimulus-deprivation or anisometropic amblyopia (irreversible cortical visual loss uncorrectable by lenses)
     • Complete loss of high-grade binocular stereopsis (loss of 3-dimensional stereoscopic depth perception)
     • Suppressive scotoma and sensory strabismus

1. Physical Findings and Diagnosis:
   • Physical Findings: Markedly erythematous, bulging superior pole of the left anterior tonsillar pillar and soft palate, medial and downward displacement of the left palatine tonsil, and deviation of the edematous uvula toward the contralateral (right) side.
   • Definitive Diagnosis: Acute Left Peritonsillar Abscess (Quinsy).
2. Anatomical Space and Pathophysiology:
   • Anatomical Location: The potential peritonsillar space situated between the true fibrous capsule of the palatine tonsil medially and the superior pharyngeal constrictor muscle laterally.
   • Pathophysiology: Usually arises as a suppurative complication following acute exudative tonsillitis or micro-abscess formation within Weber's salivary glands (minor salivary glands in the supra-tonsillar fossa) that penetrates the tonsillar capsule, dissecting into the loose peritonsillar areolar tissue. Trismus occurs secondary to inflammatory spasm and irritation of the adjacent internal pterygoid muscle.
3. Microbial Etiology:
   • Aerobic pathogens:
     • Streptococcus pyogenes (Group A beta-hemolytic Streptococcus - most common)
     • Streptococcus anginosus (Streptococcus milleri group)
     • Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA])
     • Haemophilus influenzae
   • Anaerobic pathogens:
     • Fusobacterium necrophorum
     • Prevotella and Porphyromonas species
     • Peptostreptococcus species
4. Life-Threatening Complications:
   • Descending necrotizing mediastinitis (via the lateral pharyngeal space into the retropharyngeal and "danger space")
   • Parapharyngeal space abscess with internal jugular vein septic thrombophlebitis (Lemierre syndrome)
   • Erosion or pseudoaneurysm rupture of the internal carotid artery
   • Acute upper airway compromise / laryngeal edema leading to asphyxiation
   • Aspiration pneumonia or lung abscess secondary to spontaneous internal rupture of the abscess into the airway
5. Management Strategy:
   • Interventional Procedure:
     • Needle aspiration with an 18–20 gauge needle (diagnostic and therapeutic) or formal Incision and Drainage (I&D) performed at the point of maximal fluctuance (typically midway between the base of the uvula and the upper third molar) under local mucosal anesthesia.
     • Alternative/Interval: Quinsy tonsillectomy (abscess tonsillectomy) in patients with recurrent tonsillitis or failed drainage.
   • Empirical Parenteral Antibiotic Regimen:
     • Ampicillin-Sulbactam: $200\text{ to }300\text{ mg/kg/day}$ (based on ampicillin component) IV divided every 6 hours (maximum: $3\text{ g}$ every 6 hours)
     • OR
     • Ceftriaxone: $50\text{ to }75\text{ mg/kg/day}$ IV once daily or divided every 12 hours PLUS Clindamycin: $30\text{ to }40\text{ mg/kg/day}$ IV divided every 8 hours (maximum: $900\text{ mg/dose}$)
     • Adjunct: Intravenous Dexamethasone ($0.15\text{ to }0.3\text{ mg/kg/dose}$, maximum $10\text{ mg}$) to accelerate resolution of trismus, pain, and pharyngeal edema.

1. Biomicroscopic Findings and Diagnosis:
   • Findings: A discrete, elevated, pinkish-white inflammatory nodule situated at the limbal junction (corneolimbal border), surrounded by localized, triangular, wedge-shaped conjunctival and episcleral vascular engorgement whose apex points toward the limbal lesion.
   • Diagnosis: Phlyctenular Keratoconjunctivitis (Phlyctenulosis).
2. Immunologic Pathophysiology:
   • It represents a localized Type IV (delayed-type) cell-mediated hypersensitivity reaction of the corneal and conjunctival tissue to foreign microbial antigens (bacterial proteins or cell wall components) to which the host has been previously sensitized.
   • Sensitized T-lymphocytes release inflammatory cytokines (interferon-gamma, TNF-alpha) upon restimulation, recruiting macrophages, polymorphonuclear leukocytes, and creating localized subepithelial tuberculoid-like inflammatory granulomas (phlyctens) that undergo central necrosis and ulceration.
3. Microbial Triggers:
   • Staphylococcus aureus (cell wall teichoic acid and protein A antigens secondary to chronic staphylococcal blepharokeratoconjunctivitis / meibomian gland disease - most common globally)
   • Mycobacterium tuberculosis (tubercular protein hypersensitivity - highly prevalent in endemic regions like India)
   • Chlamydia trachomatis (lymphogranuloma venereum or chronic trachoma)
   • Helicobacter pylori, Blastocystis hominis, or intestinal parasite infestations (e.g., Ascaris lumbricoides)
4. Diagnostic Workup:
   • Chest Radiography (CXR / Chest X-ray): Posteroanterior view to evaluate for active or old pulmonary tuberculosis (lymphadenopathy, parenchymal infiltrates).
   • Tuberculin Skin Testing (Mantoux test / PPD) or Interferon-Gamma Release Assay (IGRA) to confirm mycobacterial sensitization.
   • Eyelid and Conjunctival Swab Culture: For bacterial culture, Gram stain, and sensitivity (to evaluate for S. aureus blepharitis).
   • Stool Examination: For ova and parasites (routine microscopy).
5. Therapeutic Regimen:
   • Acute Ocular Therapy:
     • Topical Corticosteroids: Prednisolone acetate 1% ophthalmic suspension or Fluorometholone 0.1% drops, 1 drop 4 times daily for 5–7 days, followed by a rapid taper once the nodule resolves (ensuring corneal ulceration is non-infectious / fluorescein-negative for herpes simplex before initiation).
     • Topical Antibiotics: Moxifloxacin 0.5% or Tobramycin 0.3% eye drops 3 to 4 times daily to treat comorbid bacterial blepharoconjunctivitis.
     • Topical Cycloplegic: Homatropine 2% or Cyclopentolate 1% drops twice daily if there is marked ciliary spasm or photophobia.
   • Etiology-Specific & Preventive Therapy:
     • Lid Hygiene: Warm compresses, eyelid margin scrubs with dilute baby shampoo, and application of topical erythromycin or azithromycin 1% eye ointment to the lid margin at bedtime for blepharitis.
     • Oral Antimicrobial / Anti-inflammatory: For recurrent or blepharitis-associated phlyctenulosis in children older than 8 years, oral Doxycycline ($100\text{ mg}$ daily) or oral Azithromycin ($10\text{ mg/kg/day}$ for 3 days weekly) or oral Erythromycin ($30\text{ to }50\text{ mg/kg/day}$ divided every 6–8 hours) for younger children.
     • Anti-Tubercular Therapy (ATT): Standard full-course weight-based antitubercular therapy if active clinical or radiological tuberculosis is confirmed, or isoniazid preventive therapy (IPT) if latent tuberculosis infection is diagnosed.

• Unlike infectious bacterial corneal ulcers, a phlycten begins as a localized subepithelial nodule that breaks down to form a shallow grey ulcer (phlyctenular ulcer).
• When a limbal phlycten migrates centrally toward the cornea, it carries a leash of superficial blood vessels in its wake; this is known as a fascicular ulcer or fascicular keratitis, leaving a classic straight band of corneal scarring.
• Always perform a fluorescein stain before instilling topical steroids: if a dendrite or large epithelial defect is present, steroids must be withheld due to risk of corneal perforation or viral exacerbation.

1. Diagnosis & Anatomical Boundary:
   • Diagnosis: Preseptal cellulitis (periorbital cellulitis).
   • Anatomical Boundary: The orbital septum (a fibrous sheet extending from the orbital periosteum into the tarsal plates). Preseptal cellulitis is confined anterior/superficial to the orbital septum, whereas orbital cellulitis involves structures posterior to it.
2. Predisposing Sources:
   • Superficial cutaneous trauma, insect bites, or abrasions of the eyelid/face.
   • Localized adnexal infections (e.g., acute hordeolum, chalazion, acute dacryocystitis).
   • Contiguous spread from upper respiratory tract infection or paranasal sinusitis (most commonly anterior ethmoiditis).
3. Common Bacterial Pathogens:
   • Staphylococcus aureus (both methicillin-susceptible [MSSA] and methicillin-resistant [MRSA]).
   • Streptococcus pneumoniae.
   • Streptococcus pyogenes (Group A Streptococcus).
   • (Historical note: Haemophilus influenzae type b is now rare due to routine immunization).
4. Signs Ruling Out Postseptal Extension:
   • Absence of proptosis (normal exophthalmometry).
   • Normal, painless extraocular motility (absence of external ophthalmoplegia or pain on ocular movement).
   • Normal pupillary light reflex (absence of a Relative Afferent Pupillary Defect [RAPD]).
   • Preserved visual acuity and color vision.
5. Empirical Antibiotic Dosing:
   • Drug: Oral Amoxicillin-Clavulanate (7:1 or 14:1 high-dose formulation).
   • Dose: 80 to 90 mg/kg/day (based on amoxicillin component) divided every 12 hours.
   • Calculation for an 11 kg child:
     $$ > \begin{aligned} > \text{Daily Dose} &= 11\text{ kg} \times 90\text{ mg/kg/day} = \mathbf{990\text{ mg/day}} \\ > \text{Dose per administration} &= \frac{990}{2} \approx \mathbf{495\text{ to }500\text{ mg PO twice daily}} > \end{aligned} > $$
   • Duration: 7 to 10 days, with close re-evaluation within 24–48 hours for clinical improvement.

graph TD
    A[Acute Eyelid Swelling & Erythema] --> B{Examine Orbital Signs}
    B -->|Proptosis, Pain on EOM, Decreased Vision, RAPD| C[Orbital Cellulitis Postseptal]
    B -->|Normal EOM, No Proptosis, Preserved Vision, Normal Pupillary Reflex| D[Preseptal Cellulitis]
    C --> E[Emergent Contrast CT Orbits + IV Ceftriaxone + Vancomycin + Urgent Ophthalmology/ENT Consult]
    D --> F{Child > 1 yr, Mild, Systemically Well?}
    F -->|Yes| G[Oral Amoxicillin-Clavulanate or Cefpodoxime; 24-48h Follow-up]
    F -->|No / Toxic / Unresponsive| H[Admit for IV Cefuroxime / Ampicillin-Sulbactam +/- Vancomycin]

1. Diagnosis:
   • Pterygium (right eye).
2. Typical Location & Progression:
   • Located predominantly in the nasal interpalpebral bulbar conjunctiva, advancing horizontally across the limbal border onto the clear superficial cornea towards the visual axis (temporal occurrence is rare).
3. Histopathological Findings:
   • Elastotic degeneration of subconjunctival stromal collagen (formation of abnormal, fragmented, basophilic elastotic fibers).
   • Stromal hyalinization and active fibrovascular proliferation.
   • Overlying conjunctival epithelial hyperplasia or thinning with chronic lymphocytic inflammatory infiltrate.
4. Environmental Risk Factors:
   • Chronic, unprotected exposure to solar ultraviolet (UV-B) radiation.
   • Prolonged exposure to hot, dry, dusty, or windy microenvironments (e.g., outdoor agricultural work within the "pterygium belt").
5. Management:
   • Medical (Symptomatic): Topical preservative-free lubricating eye drops/ointments, short-course topical non-steroidal anti-inflammatory drops or mild topical steroids (e.g., Fluorometholone 0.1%) during inflamed episodes, and UV-blocking sunglasses.
   • Definitive Surgical Management:
     • Indications: Encroachment within 3–4 mm of the visual axis, significant induced astigmatism, persistent visual restriction, or unresolved chronic irritation.
     • Procedure: Complete surgical excision of the head and body combined with autologous conjunctival limbal autograft (CAG) or amniotic membrane transplantation (AMT), secured using fibrin glue or 8-0/10-0 absorbable sutures to reduce recurrence rates (<5% vs >40% with bare sclera excision).

1. Diagnosis:
   • Retinal detachment (RD).
2. Pathophysiological Types:
   • Rhegmatogenous retinal detachment (RRD): Separation caused by fluid passing from the vitreous cavity into the subretinal space through a full-thickness retinal break/tear.
   • Tractional retinal detachment (TRD): Pulling of the neurosensory retina away from the retinal pigment epithelium by fibrovascular or vitreoretinal membranes.
   • Exudative / Serous retinal detachment: Accumulation of subretinal fluid in the absence of retinal breaks or traction, caused by hydrostatic, inflammatory, or neoplastic vascular leakage.
3. Predisposing Pediatric Risk Factors:
   • Ocular blunt or penetrating trauma (leading cause of pediatric RD).
   • High axial myopia with peripheral lattice degeneration.
   • Retinopathy of prematurity (cicatricial stage 4/5).
   • Connective tissue dysplasias (e.g., Stickler syndrome, Marfan syndrome).
   • Pediatric intraocular surgeries (aphakic/pseudophakic detachment following congenital cataract surgery).
   • Ocular inflammatory/vascular conditions (e.g., Coats disease, familial exudative vitreoretinopathy [FEVR]).
4. Diagnostic Funduscopic Signs:
   • Elevated, corrugated, mobile, grayish-white neurosensory retina with loss of choroidal background visibility.
   • Identification of a causative full-thickness retinal break (horseshoe tear, atrophic hole, or retinal dialysis).
   • Shafer's sign ("tobacco dust" or pigmented cells in the anterior vitreous face).
   • Undulating shifting of subretinal fluid with head repositioning (in exudative RD) or taut tented-up retina without tears (in tractional RD).
5. Diagnostic Investigations & Surgical Modalities:
   • Investigations:
     • B-scan ocular ultrasonography (especially useful when dense media opacity/vitreous hemorrhage precludes fundus visualization; demonstrates a high-amplitude, mobile, folded hyperechoic membrane tethered to the optic disc).
     • Optical Coherence Tomography (OCT) of the macula (to document macula-on vs macula-off status).
   • Surgical Modalities:
     • Scleral buckling (encircling band/explant to appose the RPE to the retinal break; primary procedure of choice in pediatric phakic RRD).
     • Pars plana vitrectomy (PPV) with internal drainage, endolaser photocoagulation, and intraocular tamponade (gas [C3F8/SF6] or silicone oil).
     • Pneumatic retinopexy (selected superior breaks in cooperative adolescents).
     • Laser photocoagulation or cryopexy around identifiable tears.

1. Diagnosis:
   • Retinitis pigmentosa (RP).
2. Classic Fundoscopic Triad:
   • Bone-spicule pigmentation: Perivascular, dark melanin pigment clumps concentrated in the mid-peripheral retina.
   • Arteriolar attenuation: Marked, diffuse thinning and narrowing of retinal vessels.
   • Waxy disc pallor: Characteristic yellowish, waxy pallor of the optic nerve head.
3. Modes of Inheritance:
   • Autosomal Recessive (AR): Most common mode (accounts for ~60–70% of non-sporadic cases; e.g., mutations in USH2A, PDE6A, PDE6B).
   • Autosomal Dominant (AD): Accounts for ~15–25% (e.g., RHO gene mutations; often has a milder phenotype).
   • X-linked Recessive (XLR): Accounts for ~5–15% (e.g., RPGR gene mutations; typically early onset and most severe).
4. Syndromic Associations:
   • Usher syndrome (RP + congenital or progressive sensorineural hearing loss + vestibular dysfunction).
   • Bardet-Biedl syndrome (RP + postaxial polydactyly + central obesity + renal anomalies + cognitive impairment + hypogonadism).
   • Kearns-Sayre syndrome (Mitochondrial cytopathy: atypical "salt-and-pepper" RP + progressive external ophthalmoplegia + cardiac conduction block).
   • Refsum disease (Peroxisomal disorder: phytanic acid accumulation + RP + peripheral polyneuropathy + cerebellar ataxia + ichthyosis).
   • Neuronal Ceroid Lipofuscinosis / Batten disease (RP + progressive cognitive/motor regression + epilepsy).
5. Electrophysiological Confirmation:
   • Gold-Standard Test: Full-field electroretinography (ffERG).
   • Pathognomonic Abnormality: Selective and early extinction or marked amplitude reduction of scotopic (dark-adapted) rod-driven b-waves, with preserved or relatively spared photopic (light-adapted) cone responses early on, progressing to a flat / extinguished (undetectable) electroretinogram in advanced disease.

1. Diagnosis:
   • Retinoblastoma (left eye).
2. Genetic Transmission Comparison:
   • Gene Involved: RB1 tumor suppressor gene located on chromosome 13q14 (follows Knudson's "two-hit" hypothesis).
   • Heritable / Germline Form (~40% of cases):
     • Genetics: First hit is inherited in the germline; second hit occurs somatically. Autosomal dominant transmission with ~90% penetrance.
     • Laterality: Typically bilateral and/or multifocal.
     • Secondary Neoplasm Risk: Markedly elevated lifelong risk of non-ocular malignancies (e.g., osteosarcoma, soft tissue sarcomas, melanoma) and trilateral retinoblastoma (associated midline neuroblastic tumors like pinealoblastoma).
   • Non-heritable / Somatic Form (~60% of cases):
     • Genetics: Both hits occur as spontaneous somatic mutations in a single retinal progenitor cell.
     • Laterality: Exclusively unilateral and unifocal.
     • Secondary Neoplasm Risk: No increased risk of secondary non-ocular cancers.
3. Signs & Mechanism:
   • Primary Sign: Leukocoria (white pupillary reflex or "amaurotic cat's eye reflex").
   • Mechanism: Normal red fundus reflex is replaced by light reflecting off a whitish-cream, vascularized, elevated intraocular tumor mass protruding into the vitreous cavity.
   • Second Most Common Sign: Strabismus (sensory esotropia or exotropia resulting from visual axis occlusion and loss of macular fixation).
4. Contraindication to Biopsy:
   • Intraocular needle biopsy / fine needle aspiration biopsy (FNAB) is strictly contraindicated because breaching the sclera and ocular coats carries a high risk of extraocular tumor seeding along the needle tract, converting an intraocular tumor into an aggressive orbital recurrence with lethal systemic dissemination.
5. Imaging & Pathognomonic Finding:
   • Modality of Choice: High-resolution Magnetic Resonance Imaging (MRI) of the orbits and brain with contrast (to assess optic nerve infiltration, extraocular extension, and pineal gland involvement) complemented by B-scan ocular ultrasonography.
   • Pathognomonic Feature: Presence of an intraocular calcified mass (clumpy intratumoral calcification, highly acoustic/hyperreflective with posterior acoustic shadowing on B-scan USG; hyperdense foci on non-contrast CT).

graph TD
    A[Child with Leukocoria / Strabismus] --> B[Urgent Ophthalmologic Exam under Anesthesia + Red Reflex]
    B --> C[B-scan USG + High-Resolution Orbit/Brain MRI]
    C --> D{Evaluate International Intraocular Classification}
    D -->|Group A to C: Early/Focal| E[Eye-Sparing Focal Therapy: Transpupillary Thermotherapy, Cryotherapy, Intra-Arterial Chemotherapy IAC]
    D -->|Group D: Advanced Multifocal| F[Intra-Arterial Chemotherapy IAC / Systemic Chemoreduction + Focal Consolidation]
    D -->|Group E: Extensive/Blind/Neovascular Glaucoma| G[Primary Enucleation with Long Optic Nerve Stump]
    C --> H[Genetic Testing: RB1 Gene Mutation Analysis + Genetic Counseling]

1. Diagnosis & Retinal Finding:
   • Retinopathy of Prematurity (ROP).
   • Demarcation line / elevated ridge separating the vascularized posterior retina from the anterior avascular peripheral retina, characteristic of active Stage 2 / Stage 3 ROP with vascular tortuosity and engorgement.
2. Associated Non-Gestational Risk Factors:
   • Unmonitored supplemental oxygen exposure and hyperoxia-hypoxia fluctuations.
   • Prolonged mechanical ventilation and surfactant requirement.
   • Neonatal sepsis and systemic inflammation.
   • Frequent packed red blood cell (PRBC) transfusions.
   • Poor postnatal weight gain during the first 6 weeks of life.
3. Screening Timeline:
   • For infants born at $<28$ weeks gestation or $<1000\text{ g}$ birth weight: Initial screening is performed at 2 to 3 weeks of chronological age (or at 30 to 31 weeks postmenstrual age, whichever is later).
   • For preterm infants born at $\ge 28$ weeks: Screen at 4 weeks of postnatal life or 30 days of age ("Tees Din / Day 30" strategy).
4. Criteria for Type 1 ROP (High-Risk Pre-Threshold Requiring Treatment within 48–72 Hours):
   • Zone I, any stage with Plus disease.
   • Zone I, Stage 3 without Plus disease.
   • Zone II, Stage 2 or Stage 3 with Plus disease.

graph TD
    A[Phase 1: Hyperoxia & Loss of Placenta] -->|Suppresses| B[Downregulated VEGF & IGF-1]
    B --> C[Arrest of Normal Retinal Vascularization]
    C --> D[Phase 2: Metabolic Demand of Developing Retina]
    D -->|Tissue Hypoxia| E[Marked Upregulation of VEGF & Erythropoietin]
    E --> F[Pathologic Neovascularization & Shunt Formation]
    F -->|Fibrovascular Proliferation| G[Tractional Retinal Detachment Stage 4/5]

1. Diagnosis:
   • Right Esotropia (infantile / non-accommodative convergent strabismus).
2. Bedside Clinical Screening Tests:
   • Hirschberg corneal light reflex test (decentered reflex temporally in the affected eye; $1\text{ mm} \approx 7^\circ \approx 15\text{ prism diopters}$).
   • Cover-uncover test (evaluates heterotropia / manifest deviation).
   • Alternate (cross) cover test (measures total deviation, including latent phorias).
   • Brückner red reflex test (unequal brightness of fundus red reflexes between eyes using direct ophthalmoscope).
3. Concomitant vs. Incomitant Strabismus:
   • Concomitant (Comitant): The angle of ocular misalignment remains identical in all cardinal directions of gaze and regardless of which eye fixates; typically non-paralytic (e.g., infantile esotropia).
   • Incomitant (Paralytic/Restrictive): The angle of deviation varies depending on the direction of gaze and the fixating eye; secondary to cranial nerve palsy (CN III, IV, VI) or mechanical muscle restriction (e.g., Duane syndrome, Brown syndrome, blowout fracture).
4. Sequential Management Steps:
   • Cycloplegic refraction (using 0.5% or 1% cyclopentolate/atropine) to detect and correct any accommodative refractive error.
   • Anti-amblyopia therapy: Occlusion (patching) of the preferred left eye or optical/pharmacologic penalization (atropine drops) to restore equal visual acuity.
   • Surgical realignment: Bilateral medial rectus recession or unilateral medial rectus recession with lateral rectus resection, typically performed between 6 and 24 months of age once amblyopia is controlled.

1. Diagnosis:
   • Subconjunctival hemorrhage (right temporal scleral aspect).
2. Pediatric Etiologies:
   • Acute Valsalva maneuvers (severe paroxysmal coughing, vomiting, sneezing, or breath-holding/straining).
   • Ocular trauma or vigorous eye rubbing.
   • Acute hemorrhagic conjunctivitis (e.g., enterovirus 70, coxsackievirus A24, adenovirus).
   • Bleeding diathesis, thrombocytopenia, or leukemia.
   • Non-accidental trauma / abusive head trauma (shaken baby syndrome).
3. Clinical Red Flags:
   • Absence of a visible posterior border (hemorrhage extending posteriorly beyond view, indicating tracking of blood from a base of skull / orbital roof fracture).
   • Bilateral spontaneous involvement or presence of associated periorbital ecchymoses ("raccoon eyes") suggesting neuroblastoma metastases or skull base fracture.
4. Management & Clinical Course:
   • Reassurance and education; no specific topical eye drops or surgical interventions are indicated.
   • Cold compresses during the first 24 hours can alleviate mild local discomfort.
   • Spontaneous resolution occurs through gradual hemoglobin degradation (shifting from bright red to brown-yellow) over 7 to 14 days without long-term sequelae.

1. WAGR Syndrome:
   • Ocular Feature: Congenital Aniridia (bilateral complete or partial absence of the iris, often with foveal hypoplasia and nystagmus).
   • Genetic Defect: Contiguous 11p13 gene deletion involving PAX6 (ocular development) and WT1 (Wilms tumor locus).
   • Surveillance: Serial renal ultrasonography every 3 months until 7–8 years of age (Wilms tumor surveillance) and monitoring for secondary glaucoma and corneal keratopathy.
2. Neurofibromatosis Type 1 (NF1):
   • Ocular Feature: Lisch nodules (melanocytic hamartomas of the iris, appearing as dome-shaped, tan/brown papules) and Plexiform neurofibromas of the eyelid (S-shaped lid margin).
   • Genetic Defect: Autosomal dominant heterozygous loss-of-function mutation in NF1 gene on chromosome 17q11.2, encoding neurofibromin (RAS-MAPK pathway dysregulation).
   • Surveillance: Annual visual acuity, visual fields, and fundus examination screening for Optic Pathway Gliomas (OPG) until age 8–10 years.
3. Marfan Syndrome:
   • Ocular Feature: Ectopia lentis—specifically bilateral superotemporal (upward and outward) lens subluxation.
   • Genetic Defect: Autosomal dominant mutation in the FBN1 gene on chromosome 15q21.1, encoding fibrillin-1 (microfibril structural failure and TGF-$\beta$ upregulation).
   • Surveillance: Annual echocardiography (monitoring aortic root dilation / dissection) and dilated funduscopic evaluation for high myopia and rhegmatogenous retinal detachment.
4. Classic Galactosemia:
   • Ocular Feature: "Oil-drop" nuclear cataracts.
   • Genetic Defect: Autosomal recessive deficiency of Galactose-1-phosphate uridylyltransferase (GALT gene on chromosome 9p13), causing accumulation of galactitol in the lens via aldose reductase.
   • Surveillance: Immediate lifetime dietary elimination of galactose/lactose (reverses early lens opacities); long-term neurodevelopmental and hypergonadotropic hypogonadism tracking.

1. Identification:
   • Image A: Rinne test (comparing Air Conduction [AC] to Bone Conduction [BC]).
   • Image B: Weber test (evaluating bone conduction lateralization).
2. Tuning Fork Frequency:
   • Preferred frequency: $512\text{ Hz}$.
   • Rationale: Provides optimal decay time without tactile sensation. Lower frequencies ($128\text{ Hz}$ or $256\text{ Hz}$) generate vibrotactile somatosensory stimuli on the mastoid rather than pure auditory perception. Higher frequencies ($1024\text{ Hz}$ or $2048\text{ Hz}$) have a brief vibration decay time and air conduction predominantly overrides bone conduction before measurement can occur.
3. Expected Results for Right Otitis Media with Effusion (Right Conductive Hearing Loss):
   • Test A (Right Rinne): Rinne Negative ($\text{BC} > \text{AC}$ or $\text{BC} \ge \text{AC}$).
   • Test A (Left Rinne): Rinne Positive ($\text{AC} > \text{BC}$, normal left ear).
   • Test B (Weber): Lateralizes to the Right ear (the ear with conductive impairment, due to absence of environmental masking noise and occlusion effect).
4. False Negative Rinne:
   • Definition: When a patient with severe-to-profound unilateral sensorineural hearing loss appears to have a "negative" Rinne test ($\text{BC} > \text{AC}$) in the affected dead ear.
   • Mechanism: The sound from the tuning fork placed on the diseased mastoid process travels through cranial bone across the skull base and is perceived by the normal contralateral cochlea ("transcranial cross-hearing").
   • Confirmation: Schwabach test or Absolute Bone Conduction (ABC) test with tragic occlusion, or performing the Weber test (which will lateralize to the normal hearing contralateral ear, contradicting a true conductive lesion).

1. Anatomical Site & Pupillary Light Reflex Findings (Patient A):

   • Lesion site: Right optic nerve (pre-chiasmatic lesion anterior to the optic chiasm).
   • Light shone into the right (affected) eye:
     • Direct pupillary reflex (right eye): Absent (no constriction).
     • Consensual pupillary reflex (left eye): Absent (no constriction).
     • Mechanism: Complete afferent pupillary defect (amaurotic pupil) due to disruption of afferent sensory impulses via cranial nerve II.
   • Light shone into the left (unaffected) eye:
     • Direct pupillary reflex (left eye): Present (normal brisk constriction).
     • Consensual pupillary reflex (right eye): Present (normal brisk constriction), confirming intact bilateral efferent parasympathetic innervation via cranial nerve III (oculomotor nerve).

2. Lesion Site and Etiology (Patient B):

   • Anatomical site: Central optic chiasm (compression of crossing nasal hemiretinal fibers decussating at the midline, which subserve temporal visual fields).
   • Most common pediatric tumor: Craniopharyngioma (specifically the adamantinomatous histopathological subtype in children).
   • Embryological cell of origin: Ectodermal remnants of Rathke's pouch (the embryonic stomodeal invagination that forms the anterior pituitary/adenohypophysis).

3. Retrochiasmal Visual Pathway Localization:

   • Contralateral superior homonymous quadrantanopia ("pie-in-the-sky"): Lesion of Meyer's loop within the temporal lobe (disrupting inferior retinal fibers coursing anteriorly around the temporal horn of the lateral ventricle before heading to the lingual gyrus of the primary visual cortex).
   • Contralateral homonymous hemianopia with macular sparing: Lesion of the primary visual cortex (Brodmann area 17/striate cortex) in the occipital lobe, typically caused by posterior cerebral artery (PCA) occlusion. Macular vision is spared due to dual collateral blood supply from the middle cerebral artery (MCA) and a disproportionately large occipital pole representation.

4. Perioperative Endocrine Replacement Protocol:

   • Central Adrenal Insufficiency:
     • Hydrocortisone sodium succinate: Stress-dose coverage of $50\text{--}100\text{ mg/m}^2/\text{day}$ IV (or $2\text{--}3\text{ mg/kg/day}$ IV) divided every 6 hours, initiated prior to induction of anesthesia and tapered postoperatively as physiological stress diminishes.
   • Central Diabetes Insipidus (CDI):
     • Desmopressin (1-deamino-8-D-arginine vasopressin / DDAVP): $0.5\text{--}1\ \mu\text{g}$ IV or SC every 12 to 24 hours (or oral formulation $0.05\text{--}0.1\text{ mg}$ q8–12h in stable enteral states).
     • Titrated carefully against strict fluid balance, aiming for urine output of $1.5\text{--}2.5\text{ mL/kg/h}$, urine specific gravity $>1.010$, and serum sodium maintained within $135\text{--}145\text{ mEq/L}$ to prevent cerebral edema or pontine myelinolysis.

Visual Field Pathway Mapping

[Visual Fields]
Temporal Field ──> Nasal Retina ──> Optic Nerve ──> Chiasm (Decussates) ──┐
                                                                         ├──> Optic Tract ──> LGN
Nasal Field    ──> Temporal Retina ──> Optic Nerve ──> Chiasm (Uncrossed) ──┘

                                     ┌──> Meyer's Loop (Temporal Lobe) ──> Lingual Gyrus (Inferior Striate)
LGN (Lateral Geniculate Nucleus) ────┤
                                     └──> Baum's Loop (Parietal Lobe)  ──> Cuneus Gyrus (Superior Striate)

Summary of Visual Pathway Lesion Patterns